Pibrentasvir / 100mg

Pibrentasvir is a direct-acting antiviral agent used in combination with glecaprevir for the treatment of chronic hepatitis C virus (HCV) infection across all major genotypes (1-6). Pibrentasvir targets and inhibits the NS5A protein, a crucial component of the HCV lifecycle. The NS5A protein is involved in several essential processes, including viral RNA replication and assembly of the virus. By inhibiting NS5A, pibrentasvir disrupts these processes, effectively stopping the virus from replicating and assembling new virions (virus particles).

The combination of glecaprevir and pibrentasvir has been a significant advancement in the treatment of HCV, offering high cure rates across various patient populations, including those with challenging-to-treat genotypes or with compensated cirrhosis. Its development and approval have been part of a broader effort to improve HCV treatment outcomes, reduce the duration of treatment, and simplify therapy to a single daily oral dose, enhancing patient compliance and accessibility to effective therapy.

Articles:

-Effectiveness of Glecaprevir/Pibrentasvir for Hepatitis C: Real-World Experience and Clinical Features of Retreatment Cases

Publication Date: 3 April 2020

Ayumi Sugiura, Satoru Joshita, Yuki Yamashita, Tomoo Yamazaki, Naoyuki Fujimori, Takefumi Kimura, Akihiro Matsumoto, Shuichi Wada, Hiromitsu Mori, Soichiro Shibata, Kaname Yoshizawa, Susumu Morita, Kiyoshi Furuta, Atsushi Kamijo, Akihiro Iijima, Satoko Kako, Atsushi Maruyama, Masakazu Kobayashi, Michiharu Komatsu, Makiko Matsumura, Chiharu Miyabayashi, Tetsuya Ichijo, Aki Takeuchi, Yuriko Koike, Yukio Gibo, Toshihisa Tsukadaira, Hiroyuki Inada, Yoshiyuki Nakano, Seiichi Usuda, Kendo Kiyosawa, Eiji Tanaka and Takeji Umemura

https://doi.org/10.3390/biomedicines8040074

- Mavyret: A Pan-Genotypic Combination Therapy for the Treatment of Hepatitis C Infection

Publication Date: December 1, 2017

Ashley N. Matthew, Nese Kurt Yilmaz, and Celia A. Schiffer

https://doi.org/10.1021/acs.biochem.7b01160

-Pharmacokinetics, Safety, and Tolerability Following Single and Multiple Doses of Pibrentasvir in a First-in-Human Study

Publication Date: 02 May 2017

Chih-Wei Lin, Sandeep Dutta, Armen Asatryan, Haoyu Wang, Jack Clifton II, Andrew Campbell, Wei Liu

https://doi.org/10.1002/cpdd.350